"Reimagining Medicine to Improve and Extend Lives"
Table of Contents
1. Company Snapshot
🌍 Headquarters: Basel, Switzerland
🌐 Global Presence: 155 countries | 108,000 employees
📅 Founded: 1996 (Ciba-Geigy + Sandoz merger)
🏦 Public: NYSE/SIX: NVS | 💰 Market Cap: $210B
🔬 R&D Hubs: Switzerland, US, China
💻 Careers: Novartis Careers
2. Mission, Vision & Values
🧬 Mission:
“To discover new ways to improve and extend people’s lives”
👁️ Vision:
“To become the most valued medicines company in the world”
🌟 Core Values:
- Innovation
- Quality
- Patient Focus
Culture: 4.1/5 Glassdoor | “Science-driven with global mobility”
3. Key Leadership
| Role | Name | Leadership Style |
|---|---|---|
| CEO | Vas Narasimhan | Physician-Scientist |
| CFO | Harry Kirsch | Transformation Leader |
4. Key Milestones
2001: Launch of Gleevec (cancer breakthrough)
2018: $8.7B AveXis acquisition (gene therapy)
2022: Spun off Sandoz (generics business)
2023:
- FDA approval for Pluvicto (prostate cancer)
- Launched “Focus 5” strategy
5. Business Model & Position
💰 Revenue Streams:
- 45% Innovative Medicines
- 35% Oncology
- 20% Pharmaceuticals
🆚 Key Competitors:
| Company | Headquarters | Differentiator |
|---|---|---|
| Roche | Basel, Switzerland | Diagnostics integration |
| Pfizer | New York, USA | Vaccine dominance |
6. Industry Trends & Challenges
📈 Opportunities:
- Gene/cell therapy leadership
- China market expansion
- AI-driven drug discovery
⚠️ Challenges:
- Pricing pressures in US/EU
- Patent cliffs (2025-27)
7. Financial Health (2023)
| Metric | Value | Industry Rank |
|---|---|---|
| Revenue | $45.4B | #3 Pharma |
| R&D Investment | $9.2B | #2 in R&D spend |
| Operating Margin | 28.7% | Top 20% |
8. SWOT Analysis
💪 Strengths:
- #1 in gene therapy (Zolgensma)
- Strong oncology pipeline
📉 Weaknesses:
- Limited vaccine presence
- Sandoz spin-off revenue impact
🌱 Opportunities:
- Radioligand therapy expansion
- Digital therapeutics
⚠️ Threats:
- Biosimilar competition
- Political drug pricing reforms
9. Recent Developments
🔬 Innovations:
- Pluvicto launch (prostate cancer)
- 15 new molecular entities in Phase III
🌍 Global:
- $300M China R&D center
- Africa health initiative
10. Interview Toolkit
Must-Know:
- “Focus 5” therapeutic areas
- Radioligand therapy platform
Smart Questions:
“How is Novartis leveraging AI in clinical trials?”
11. Conclusion
Novartis leads through:
🔹 Gene therapy dominance
🔹 Precision medicine breakthroughs
🔹 Global R&D network